Overview
- At a virtual shareholder meeting, co-founder Ugur Sahin said affected staff will get socially responsible options as the company moves forward with planned closures.
- The plan covers plants in Idar-Oberstein, Marburg, and Singapore, plus the former CureVac sites in Tübingen, and could affect up to 1,860 roles.
- BioNTech said it is weighing partial or full sales of each facility and set closure targets through 2027, including a Singapore shutdown in the first quarter.
- Leaders said the company is refocusing on oncology and aims to secure approvals for several cancer treatments by 2030.
- Works councils and local officials criticized the cuts after the CureVac deal, and reporting cites a €1.1 billion net loss for 2025 as shot demand waned.